Chenjing Ye

State Key Laboratory Of Medical Genomics
Shanghai, 200025, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Mutant p53 reactivation and DNA demethylation in the treatment of AML/MDS.

Mutant p53 reactivation and DNA demethylation in the treatment of AML/MDS.

Journal: Science translational medicine

Published: August 12, 2026

1α,25(OH) 2D 3 prevents CD19 CAR-T cell exhaustion and differentiation via VDR-dependent transcriptional reprogramming.

1α,25(OH) 2D 3 prevents CD19 CAR-T cell exhaustion and differentiation via VDR-dependent transcriptional reprogramming.

Journal: Acta biochimica et biophysica Sinica

Published: December 11, 2025

Targeting the RBM39-MEK5 axis synergizes with bortezomib to inhibit the malignant growth of multiple myeloma.

Targeting the RBM39-MEK5 axis synergizes with bortezomib to inhibit the malignant growth of multiple myeloma.

Journal: Blood advances

Published: January 07, 2025

Targeting MTHFD2 alters metabolic homeostasis and synergizes with bortezomib to inhibit multiple myeloma.

Targeting MTHFD2 alters metabolic homeostasis and synergizes with bortezomib to inhibit multiple myeloma.

Journal: Cell death discovery

Published: November 21, 2024

IRF4-BLOC1S5: the first rearrangement gene identified in TEMPI syndrome.

IRF4-BLOC1S5: the first rearrangement gene identified in TEMPI syndrome.

Journal: Haematologica

Published: November 25, 2023

Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties.

Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties.

Journal: Science translational medicine

Published: April 05, 2023

SPAG5 as a novel biomarker and potential therapeutic target via regulating AKT pathway in multiple myeloma.

SPAG5 as a novel biomarker and potential therapeutic target via regulating AKT pathway in multiple myeloma.

Journal: Leukemia & lymphoma

Published: June 22, 2022

JaponiconeA induces apoptosis of bortezomib-sensitive and -resistant myeloma cells in vitro and in vivo by targeting IKK.

JaponiconeA induces apoptosis of bortezomib-sensitive and -resistant myeloma cells in vitro and in vivo by targeting IKK.

Journal: Cancer biology & medicine

Published: September 27, 2021

Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.

Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.

Journal: Molecular medicine reports

Published: October 12, 2013

Showing 1-9 of 9

Last Updated: 09/26/2026